<!DOCTYPE html>
<!-- saved from url=(0014)about:internet -->
<html lang="en" class="h-100"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
    
    <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
    <meta name="description" content="">
    <title>SEIRcast - Methodology</title>

    <!-- Tailwind CSS -->
    <link href="https://unpkg.com/tailwindcss@^1.0/dist/tailwind.min.css" rel="stylesheet" />

    <!-- Bootstrap core CSS -->

    <link
      rel="stylesheet"
      href="https://stackpath.bootstrapcdn.com/bootstrap/4.4.1/css/bootstrap.min.css"
      integrity="sha384-Vkoo8x4CGsO3+Hhxv8T/Q5PaXtkKtu6ug5TOeNV6gBiFeWPGFN9MuhOf23Q9Ifjh"
      crossorigin="anonymous"
    />

    <!-- Font Awesome -->
    <link href="./js_css_images/fontawesome/css/all.min.css" rel="stylesheet">

    <!-- Custom styles -->
    <link href="./js_css_images/style.css" rel="stylesheet">

<!-- Global site tag (gtag.js) - Google Analytics -->
<script async src="https://www.googletagmanager.com/gtag/js?id=UA-166026193-1"></script>
<script>
  window.dataLayer = window.dataLayer || [];
  function gtag(){dataLayer.push(arguments);}
  gtag('js', new Date());

  gtag('config', 'UA-166026193-1');
</script>


  </head>

  <body class="d-flex flex-column h-100">

<header>
  <!-- Navbar -->
  <nav class="navbar navbar-expand-md navbar-light bg-white">
    <a class="navbar-brand" href="index.html">SEIRcast</a>
    <button class="navbar-toggler" type="button" data-toggle="collapse" data-target="#navbarCollapse" aria-controls="navbarCollapse" aria-expanded="false" aria-label="Toggle navigation">
      <span class="navbar-toggler-icon"></span>
    </button>
    <div class="collapse navbar-collapse" id="navbarCollapse">
      <ul class="navbar-nav mr-auto">
        <li class="nav-item">
          <a class="nav-link" href="index.html">Home</a>
        </li>
        <li class="nav-item active">
          <a class="nav-link" href="methodology.html">Methodology <span class="sr-only">(current)</span></a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="publications.html">Publications</a>
        </li>
        <li class="nav-item">
          <a class="nav-link" href="mailto:emichael443@usf.edu?subject=COVID-19%20Forecasting%20and%20Planning%20Portal">Contact</a>
        </li>
      </ul>
      <ul class="navbar-nav">
        <li class="nav-item active">
          <!-- <a class="nav-link" href="#">Login <span class="sr-only">(current)</span></a> -->
        </li>
      </ul>
    </div>
  </nav>
</header>

<main role="main">


<!-- Descriptions -->

<div class="bg-100">
  <div class="container py-5">
        <p class="small-title mb-1">Methodology</p>
        <h2>COVID-19 Model Structure</h2>
        <p>We have developed a compartmental model based on a general SEIR model structure which has been widely used for modelling the coronavirus pandemic to date (Peng et al., Chuynet, Lin et al., Yang et al.). The model tracks the proportion of the population that falls into the following classes:</p>
    <div class="row">
      <div class="col-lg-6">
        <ol class="ordered-list">
          <li>Susceptible individuals (<b>S</b>)</li>
          <li>Individuals who are protected as a result of public health measures such as lockdown policies (<b>R<sub>1</sub></b>)</li>
          <li>Exposed individuals who have been infected but are not yet infectious (<b>E</b>)</li>
          <li>Infectious individuals who are asymptomatic (<b>I<sub>A</sub></b>)</li>
          <li>Infectious individuals who are presymptomatic (<b>I<sub>P</sub></b>)</li>
          <li>Infectious individuals who have mild symptoms (<b>I<sub>M</sub></b>)</li>
          <li>Infectious individuals who have severe symptoms and are therefore hospitalized (<b>I<sub>H</sub></b>, the “H” state)</li>
          <li>Infectious individuals who are hospitalized and are in critical condition requiring an ICU and/or a ventilator (<b>I<sub>C</sub></b>, the “ICU” state)</li>
          <li>Individuals who die from COVID-19 disease (<b>D</b>)</li>
          <li>Individuals who recover from COVID-19 disease (<b>R<sub>2</sub></b>)</li>
          <li>Individuals who are quarantined (contact tracing) (<b>Q</b>)</li>
        </ol>
      </div>
      <div class="col-lg-6">
        <div class="bg-white pt-3 px-4 pb-2 mb-4 border">
          <img class="img-fluid center-eqn mt-2 mb-4" src="./js_css_images/model-equations.png">
        </div>
      </div>
    </div>

        <p>A diagram outlining the relationship between these classes is shown in Figure 1. The model equations describing the movement in and out of each of the 11 classes follow the diagram.</p>

        <div class="row">
          <div class="col-lg-9">
            <img class="img-fluid" src="./js_css_images/graphic_model.png">
          </div>
          <div class="col-lg-3">
            <p class="text-sm pt-3"><b><span class="text-transform: uppercase">Figure 1.</span> COVID-19 SEIR epidemic model structure.</b> Arrows between compartments demonstrate the possible transitions between disease states and the accompanying variables refer to the transition rates which are detailed in Table 1. Dashed arrows are used to show the dependence of transmission on the infectious classes.</p>
          </div>
        </div>
  </div> <!-- /container -->
</div>



  <div class="container">
        <h2>Parameters</h2>
        <p>Parameter definitions and proposed values are given in Table 1.</p>
        <p>The parameters can be defined as a distribution from which we can sample values to generate prediction confidence intervals using a Monte-Carlo sampling approach. Table 1 lists the prior parameter values used to initiate the model, and we use Bayesian updating methods to refine these initial values with evolving data on the epidemic to obtain posterior values sequentially. We use data on cumulative confirmed cases and deaths from the COVID-19 disease, as reported daily for US counties in the Johns Hopkins University (JHU) database, in running the sequential calibration of our model. Although we begin with 50,000 samples of parameter vectors drawn randomly from the prior values, and use a Relative RMSE procedure to select 200 best fitting models to the joint cumulative case and death data for generating outputs of interest.</p>
<p>The effectiveness of lockdown in a county  can be  approximated by using data on movement reductions, as provided in the <a href="https://www.unacast.com/covid19/social-distancing-scoreboard" target="_blank">unacast toolkit</a>. Updates on these movements as lockdowns are eased will be used in conjunction with changes in cases and deaths to forecast the impact of various lockdown lifting measures. Similarly, data on rates at which implemented surveillance and testing regimes are able to detect infectious cases will be used to model the impact of testing and isolation on mitigating virus transmission as lockdowns are lifted. The impacts of various social distancing measures are modelled via variable reductions in the transmission rate at this stage.</p>

            <p class="text-sm pt-3"><b><span class="text-transform: uppercase">Table 1.</span></b> Model parameters definitions and values. Note: we are still reviewing literature to understand how we can use existing data to estimate transition rates.</p>

<div class="table-responsive-md">
<table class="table table-striped table-sm">
  <thead>
    <tr>
      <th scope="col">Parm</th>
      <th scope="col">Definition</th>
      <th scope="col">Prior range</th>
      <th scope="col">Units/notes</th>
      <th scope="col">Published values</th>
      <th scope="col">References</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <th>β</th>
      <td>Infection transmission rate</td>
      <td>0.1428 – 1.5</td>
      <td>Estimated as R0*gamma in SIR model</td>
      <td>R0 = 2-6<br>β = 0.6 – 1.7</td>
      <td>Peng, Lin, Read, MMWR</td>
    </tr>
    <tr>
      <th>L</th>
      <td>Lockdown ratio</td>
      <td>5-10</td>
      <td>Ratio of population under lockdown to susceptible population</td>
      <td>—</td>
      <td>—</td>
    </tr>
    <tr>
      <th>α</th>
      <td>Rate of entering lockdown</td>
      <td>2.0 (fixed)</td>
      <td>Controls how quickly lockdown is enforced, linked to lockdown ratio and lambda</td>
      <td>Model structure proposed by Peng</td>
      <td>Peng</td>
    </tr>
    <tr>
      <th>λ</th>
      <td>Rate of leaving lockdown</td>
      <td>= alpha/L</td>
      <td>—</td>
      <td>Model structure proposed by Jiwei</td>
      <td>Jiwei</td>
    </tr>
    <tr>
      <th>σ</th>
      <td>Rate of moving from exposed class to infectious class</td>
      <td>0.16 – 0.5</td>
      <td>1/σ is the latent period; assumed 2-6 days</td>
      <td>2.2-6 days latent period</td>
      <td>Sanche</td>
    </tr>
    <tr>
      <th>p</th>
      <td>Proportion of exposed who become asymptomatic</td>
      <td>0.25 – 0.5</td>
      <td>—</td>
      <td>—</td>
      <td>CEBM, Qiu</td>
    </tr>
    <tr>
      <th>γ<sub>A</sub></th>
      <td>Recovery rate of asymptomatic cases</td>
      <td>0.125 – 0.33</td>
      <td>1/γA is the infectious period; assumed 3-8 days</td>
      <td>3-14 days infectious period, most &lt;= 8 days</td>
      <td>Sanche, Read, Lipsitch, Prem, Peak, Maier</td>
    </tr>
    <tr>
      <th>γ<sub>M</sub></th>
      <td>Recovery rate of cases with mild symptoms</td>
      <td>0.125 – 0.33</td>
      <td>1/γM is the infectious period; assumed 3-8 days</td>
      <td>3-14 days infectious period, most &lt;= 8 days</td>
      <td>Sanche, Read, Lipsitch, Prem, Peak, Maier</td>
    </tr>
    <tr>
      <th>γ<sub>H</sub></th>
      <td>Recovery rate of cases with severe symptoms requiring hospitalization</td>
      <td>0.125 – 0.33</td>
      <td>1/γH is the infectious period of severe cases; assumed 3-8 days</td>
      <td>3-14 days infectious period, most &lt;= 8 days</td>
      <td>Sanche, Read, Lipsitch, Prem, Peak, Maier</td>
    </tr>
    <tr>
      <th>γ<sub>C</sub></th>
      <td>Recovery rate of cases with severe symptoms requiring intensive care</td>
      <td>0.125 – 0.33</td>
      <td>1/γC is the infectious period; assumed 3-8 days</td>
      <td>3-14 days infectious period, most &lt;= 8 days</td>
      <td>Sanche, Read, Lipsitch, Prem, Peak, Maier</td>
    </tr>
    <tr>
      <th>γ<sub>Q</sub></th>
      <td>Recovery rate of quarantined cases</td>
      <td>0.125 – 0.33</td>
      <td>1/γC is the infectious period; assumed 3-8 days</td>
      <td>3-14 days infectious period, most &lt;= 8 days</td>
      <td>Sanche, Read, Lipsitch, Prem, Peak, Maier</td>
    </tr>
    <tr>
      <th>δ<sub>1</sub></th>
      <td>Rate of moving from presymptomatic class to mild symptomatic</td>
      <td>0.1 – 1</td>
      <td>1/time from start of infectious period to illness onset; assume 1-10 days</td>
      <td>Latent period: 2-6 days; Incubation period: 2-12 days</td>
      <td>Li, Ynag, Backer, Guan, Sanche</td>
    </tr>
    <tr>
      <th>δ<sub>2</sub></th>
      <td>Rate of moving from mild case to hospitalized class</td>
      <td>0.06 – 0.25</td>
      <td>1/time from illness onset to  hospitalization; assume 4-15 days</td>
      <td>4-15 days</td>
      <td>Li, Zhou, Wang</td>
    </tr>
    <tr>
      <th>δ<sub>3</sub></th>
      <td>Rate of moving from hospitalized class to ICU</td>
      <td>0.09 – 1</td>
      <td>1/time from hospitalization to ICU; assume 1-11 days</td>
      <td>Illness onset to ICU: 6-15 days; Illness onset to hospital: 4-15 days</td>
      <td>Li, Zhou, Wang</td>
    </tr>
    <tr>
      <th>m</th>
      <td>Mortality rate of ICU class</td>
      <td>0.08 – 0.25</td>
      <td>1/time from ICU to death</td>
      <td>4-12 days</td>
      <td>Zhou</td>
    </tr>
    <tr>
      <th>ε</th>
      <td>Proportion of symptomatic cases that are not reported</td>
      <td>0.1 – 0.3</td>
      <td>Assume 10-30% of symptomatic cases are not getting tested</td>
      <td>Diagnostic rate of symptomatic 1/9 -1/3; Diagnosis rate overall 25%</td>
      <td>Jiwei, Roda</td>
    </tr>
    <tr>
      <th>X<sub>1</sub></th>
      <td>Proportion of mild cases that progress to hospital</td>
      <td>0.05 – 0.3</td>
      <td>5-30% of mild cases are hospitalized</td>
      <td>5%, 20.7-31.4%</td>
      <td>Verity, CDC MMWR</td>
    </tr>
    <tr>
      <th>X<sub>2</sub></th>
      <td>Proportion of hospital cases that progress to ICU</td>
      <td>0.2 – 0.3</td>
      <td>20-30% of hospitalized cases require an ICU</td>
      <td>26-30%</td>
      <td>Verity, Zhou, Wang, Wu</td>
    </tr>
    <tr>
      <th>X<sub>3</sub></th>
      <td>Proportion of ICU cases that die</td>
      <td>0.2 – 0.8</td>
      <td>Proportion of ICU cases that die</td>
      <td>—</td>
      <td>Zhou, Wu, Yang, and Tom’s input</td>
    </tr>
    <tr>
      <th>z<sub>1</sub></th>
      <td>Proportion of asymptomatic cases that are quarantined through contact tracing</td>
      <td>Fixed value, scenario-based</td>
      <td>Ex. 50%, 75%, 90%, depends on strength of contact tracing efforts</td>
      <td>—</td>
      <td>—</td>
    </tr>
    <tr>
      <th>z<sub>2</sub></th>
      <td>Proportion of presymptomatic cases that are quarantined through contact tracing</td>
      <td>Fixed value, scenario-based</td>
      <td>Ex. 50%, 75%, 90%, depends on strength of contact tracing efforts</td>
      <td>—</td>
      <td>—</td>
    </tr>
    <tr>
      <th>z<sub>3</sub></th>
      <td>Proportion of mild symptomatic cases that are quarantined through contact tracing</td>
      <td>Fixed value, scenario-based</td>
      <td>Ex. 50%, 75%, 90%, depends on strength of contact tracing efforts</td>
      <td>—</td>
      <td>—</td>
    </tr>
    <tr>
      <th>n<sub>1</sub></th>
      <td>Proportion of quarantined cases that require hospitalization</td>
      <td>0.05 – 0.3 </td>
      <td>Assumed equal to mild symptomatic cases, see x1</td>
      <td>—</td>
      <td>—</td>
    </tr>
    <tr>
      <th>κ</th>
      <td>Rate of moving from quarantined class to hospital</td>
      <td>0.125 – 0.33</td>
      <td>1/γH is the infectious period of severe cases; assumed 3-8 days</td>
      <td>3-14 days infectious period, most &lt;= 8 days</td>
      <td>Sanche, Read, Lipsitch, Prem, Peak, Maier</td>
    </tr>
    <tr>
      <th>d</th>
      <td>Reduction in transmission due to social distancing, face masks, etc.</td>
      <td>0.15 – 0.42</td>
      <td>—</td>
      <td>Masks are 58-85% effective</td>
      <td>Brienen</td>
    </tr>
  </tbody>
</table>
</div> <!-- /table responsive -->

  </div> <!-- /container -->

  <div class="container">
    <h2>References</h2>
    <ul class="references text-sm">
      <li><b>Peng et al.</b> <i>Epidemic analysis of COVID-19 in China by dynamical modeling</i><br><a href="https://arxiv.org/pdf/2002.06563" target="_blank">https://arxiv.org/pdf/2002.06563 <i class="far fa-file-pdf"></i></a></li>
      <li><b>Zhang et al.</b> <i>Prediction of the COVID-19 outbreak based on a realistic stochastic model</i><br><a href="https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.03.10.20033803.full.pdf" target="_blank">https://www.medrxiv.org/content/medrxiv/early/2020/03/13/2020.03.10.20033803.full.pdf <i class="far fa-file-pdf"></i></a></li>
      <li><b>Sanche et al.</b> <i>High Contagiousness and Rapid Spread of Severe Acute Respiratory Syndrome Coronavirus 2</i><br><a href="https://wwwnc.cdc.gov/eid/article/26/7/20-0282-f5" target="_blank">https://wwwnc.cdc.gov/eid/article/26/7/20-0282-f5 <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>Verity et al.</b> <i>Estimates of the severity of COVID-19 disease</i><br><a href="https://www.medrxiv.org/content/10.1101/2020.03.09.20033357v1.full.pdf" target="_blank">https://www.medrxiv.org/content/10.1101/2020.03.09.20033357v1.full.pdf <i class="far fa-file-pdf"></i></a></li>
      <li><b>Li et al.</b> <i>Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia</i><br><a href="https://www.nejm.org/doi/10.1056/NEJMoa2001316" target="_blank">https://www.nejm.org/doi/10.1056/NEJMoa2001316 <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>Backer et al.</b> <i>Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020</i><br><a href="https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.5.2000062" target="_blank">https://www.eurosurveillance.org/content/10.2807/1560-7917.ES.2020.25.5.2000062 <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>Guan et al.</b> <i>Clinical Characteristics of Coronavirus Disease 2019 in China</i><br><a href="https://www.nejm.org/doi/10.1056/NEJMoa2002032" target="_blank">https://www.nejm.org/doi/10.1056/NEJMoa2002032 <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>Zhou et al.</b> <i>Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study</i><br><a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext" target="_blank">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30566-3/fulltext <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>Wang et al.</b> <i>Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus–Infected Pneumonia in Wuhan, China</i><br><a href="https://jamanetwork.com/journals/jama/article-abstract/2761044" target="_blank">https://jamanetwork.com/journals/jama/article-abstract/2761044 <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>CDC MMWR</b> <i>Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19) — United States, February 12–March 16, 2020</i><br><a href="https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm" target="_blank">https://www.cdc.gov/mmwr/volumes/69/wr/mm6912e2.htm <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>X. Yang, Yu et al.</b> <i>Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study</i><br><a href="https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30079-5/fulltext" target="_blank">https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30079-5/fulltext <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>W. Yang, Zhang et al.</b> <i>Rational evaluation of various epidemic models based on the COVID-19 data of China</i><br><a href="https://arxiv.org/pdf/2003.05666" target="_blank">https://arxiv.org/pdf/2003.05666 <i class="far fa-file-pdf"></i></a></li>
      <li><b>Peak et al.</b> <i>Modeling the Comparative Impact of Individual Quarantine vs. Active Monitoring of Contacts for the Mitigation of COVID-19</i><br><a href="https://www.medrxiv.org/content/10.1101/2020.03.05.20031088v1.full.pdf" target="_blank">https://www.medrxiv.org/content/10.1101/2020.03.05.20031088v1.full.pdf <i class="far fa-file-pdf"></i></a></li>
      <li><b>Lai et al.</b> <i>Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): Facts and myths
</i><br><a href="https://www.sciencedirect.com/science/article/pii/S1684118220300402/pdf?md5=611742ed817ecf6bb748f40c0533c411&amp;pid=1-s2.0-S1684118220300402-main.pdf" target="_blank">https://www.sciencedirect.com/science/article/pii/S1684118220300402/pdf?md5=611742ed817ecf6bb748f40c0533c411&amp;pid=1-s2.0-S1684118220300402-main.pdf <i class="far fa-file-pdf"></i></a></li>
      <li><b>Kimball et al.</b> <i>Asymptomatic and Presymptomatic SARS-CoV-2 Infections in Residents of a Long-Term Care Skilled Nursing Facility — King County, Washington, March 2020</i><br><a href="https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e1.htm" target="_blank">https://www.cdc.gov/mmwr/volumes/69/wr/mm6913e1.htm <i class="fas fa-external-link-alt"></i></a></li>
      <li><b>Cavallo et al.</b> <i>Hospital Capacity and Operations in the Coronavirus Disease 2019 (COVID-19) Pandemic—Planning for the Nth Patient</i><br><a href="https://jamanetwork.com/channels/health-forum/fullarticle/2763353" target="_blank">https://jamanetwork.com/channels/health-forum/fullarticle/2763353 <i class="fas fa-external-link-alt"></i></a></li>
    </ul>

  </div> <!-- /container -->


</main>

<footer class="footer mt-auto py-3">

<div class="bg-100 my-3">
  <div class="container">
    <div class="row pt-4 pb-3">
      <div class="col-md-8 col-lg-6">
        <p class="text-sm">The SEIRcast COVID-19 Forecasting &amp; Planning Portal, and underlying models, is the product of collaboration between the Edwin Michael group and <a href="https://crc.nd.edu/" target="_blank">Center for Research Computing</a> at <a href="https://www.nd.edu/" target="_blank">Notre Dame</a>, with partners at the <a href="https://www.usf.edu/" target="_blank">University of South Florida</a>.</p>
      </div>
      <div class="col-md-4 col-lg-6">
        <div class="row">
          <div class="col-6 col-md-12 col-lg-6">
            <img class="img-fluid mt-2 p-2" src="./js_css_images/nd_mark_blue_m.png">
          </div>
          <div class="col-6 col-md-12 col-lg-6">
            <img class="img-fluid p-2" src="./js_css_images/usf-logo.png">
          </div>
        </div>
      </div>
    </div>
  </div> <!-- /container -->
</div>

  <div class="container text-center text-sm">
    <span>© 2020-2021 <a href="https://www.usf.edu/" target="_blank">University of South Florida</a> and <a href="https://www.nd.edu/" target="_blank">University of Notre Dame</a></span>
  </div>
</footer>

    <script
      src="https://code.jquery.com/jquery-3.4.1.slim.min.js"
      integrity="sha384-J6qa4849blE2+poT4WnyKhv5vZF5SrPo0iEjwBvKU7imGFAV0wwj1yYfoRSJoZ+n"
      crossorigin="anonymous"
    ></script>
    <script
      src="https://cdn.jsdelivr.net/npm/popper.js@1.16.0/dist/umd/popper.min.js"
      integrity="sha384-Q6E9RHvbIyZFJoft+2mJbHaEWldlvI9IOYy5n3zV9zzTtmI3UksdQRVvoxMfooAo"
      crossorigin="anonymous"
    ></script>
    <script
      src="https://stackpath.bootstrapcdn.com/bootstrap/4.4.1/js/bootstrap.min.js"
      integrity="sha384-wfSDF2E50Y2D1uUdj0O3uMBJnjuUD4Ih7YwaYd1iqfktj0Uod8GCExl3Og8ifwB6"
      crossorigin="anonymous"
    ></script>
  

</body></html>